Summary of COVID-19 tixagevimab/cilgavimab studies

5,172 patient tixagevimab/cilgavimab prophylaxis RCT: 86% lower mortality (p=0.11) and 82% fewer symptomatic cases (p<0.0001).
PrEP RCT with 3,441 tixagevimab/cilgavimab patients and 1,731 control patients, showing lower risk of symptomatic cases with treatment.
Apr 2022, New England J. Medicine, http://www.nejm.org/doi/10.1056/NEJMoa2116620, https://c19p.org/levin2

2. Montgomery et al., Efficacy and safety of intramuscular administration of tixagevimab–cilgavimab for early outpatient treatment of COVID-19 (TACKLE): a phase 3, randomised, double-blind, placebo-controlled trial

903 patient tixagevimab/cilgavimab early treatment RCT: no change in mortality (p=1), 50% lower severe cases (p=0.01), and 57% lower hospitalization (p=0.002).
RCT 910 outpatients in the USA, 456 treated with tixagevimab/cilgavimab, showing significantly lower severe cases and hospitalization with treatment, but no difference in mortality.
Jun 2022, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260022001801, https://c19p.org/montgomery

3. Holland et al., Tixagevimab–cilgavimab for treatment of patients hospitalised with COVID-19: a randomised, double-blind, phase 3 trial

1,417 patient tixagevimab/cilgavimab late treatment RCT: 30% lower mortality (p=0.03) and 7% improved recovery (p=0.21).
RCT with 710 hospitalized patients treated with tixagevimab/cilgavimab, and 707 placebo patients, showing lower mortality with treatment.
Jul 2022, The Lancet Respiratory Medicine, https://www.sciencedirect.com/science/article/pii/S2213260022002156, https://c19p.org/holland

4. Kaminski et al., COVID-19 morbidity decreases with tixagevimab–cilgavimab preexposure prophylaxis in kidney transplant recipient nonresponders or low-vaccine responders

430 patient tixagevimab/cilgavimab prophylaxis study: 92% lower mortality (p=0.07), 96% lower ICU admission (p=0.001), 95% lower hospitalization (p=0.001), and 99% fewer symptomatic cases (p=0.001).
Retrospective 430 kidney transplant recipients showing significantly lower symptomatic COVID-19 and hospitalization with tixagevimab/cilgavimab preexposure prophylaxis compared to 97 patients who did not receive it, during an omicron wave.
Oct 2022, Kidney Int., https://www.sciencedirect.com/science/article/pii/S0085253822005506, https://c19p.org/kaminski

5. Young-Xu et al., Tixagevimab/Cilgavimab for Prevention of COVID-19 during the Omicron Surge: Retrospective Analysis of National VA Electronic Data

8,087 patient tixagevimab/cilgavimab prophylaxis PSM study: 64% lower mortality (p=0.004), 69% lower combined death/hospitalization/cases (p<0.0001), 87% lower hospitalization (p=0.04), and 66% fewer cases (p=0.03).
PSM retrospective 1,848 immunocompromised patients given tixagevimab/cilgavimab prophylaxis, showing lower mortality, hospitalization, and cases.
May 2022, medRxiv, https://www.medrxiv.org/content/10.1101/2022.05.28.22275716, https://c19p.org/youngxu

6. Kertes et al., Association between AZD7442 (tixagevimab-cilgavimab) administration and SARS-CoV-2 infection, hospitalization and mortality

5,124 patient tixagevimab/cilgavimab prophylaxis study: 92% lower combined mortality/hospitalization (p=0.01) and 47% fewer cases (p=0.01).
Retrospective 825 immunocompromised individuals treated with tixagevimab-cilgavimab and 4229 untreated in Israel, showing significantly lower infection and hospitalization/death with treatment. Omicron was the dominant variant.
Jul 2022, Clinical Infectious Diseases, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac625/6651663, https://c19p.org/kertes

7. Najjar-Debbiny et al., Effectiveness of Evusheld in Immunocompromised Patients: Propensity Score-Matched Analysis

3,515 patient tixagevimab/cilgavimab prophylaxis study: 59% lower hospitalization (p=0.02) and 25% fewer cases (p=0.03).
Retrospective 732 immunocompromised patients in Israel treated with tixagevimab/cilgavimab, and 2,812 matched controls, showing significantly lower cases and hospitalization with treatment.
Oct 2022, Clinical Infectious Diseases, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac855/6780937, https://c19p.org/najjardebbiny3

8. Al Jurdi et al., Tixagevimab/cilgavimab pre-exposure prophylaxis is associated with lower breakthrough infection risk in vaccinated solid organ transplant recipients during the omicron wave

444 patient tixagevimab/cilgavimab prophylaxis study: 86% lower mortality (p=0.25), 83% lower hospitalization (p=0.12), and 66% fewer cases (p=0.001).
Retrospective cohort study of 444 solid organ transplant recipients showing significantly lower risk of SARS-CoV-2 breakthrough infections with tixagevimab/cilgavimab pre-exposure prophylaxis compared to controls during the omicron period.
Dec 2022, American J. Transplantation, https://www.sciencedirect.com/science/article/pii/S1600613523000655, https://c19p.org/aljurdi

9. Ollila et al., Seroconversion and outcomes after initial and booster COVID‐19 vaccination in adults with hematologic malignancies

37 patient tixagevimab/cilgavimab prophylaxis study: 76% lower mortality (p=0.32) and 90% fewer cases (p=0.03).
Retrospective 378 patients with hematologic malignancies analyzing seroconversion and outcomes post-vaccination. Among 25 seronegative patients after booster vaccination who received tixagevimab/cilgavimab prophylaxis, no COVID-19 infections occurred, whereas 3 infections and 1 death occurred among 12 comparable patients not receiving prophylaxis.
Jul 2022, Cancer, https://acsjournals.onlinelibrary.wiley.com/doi/10.1002/cncr.34354, https://c19p.org/ollila

10. Levin et al., AZD7442 (Tixagevimab/Cilgavimab) for Post-exposure Prophylaxis of Symptomatic COVID-19

1,121 patient tixagevimab/cilgavimab prophylaxis RCT: 42% fewer symptomatic cases (p=0.06).
1,121 patient PEP RCT showing lower symptomatic cases with tixagevimab/cilgavimab, without statistical significance.
Dec 2021, Clinical Infectious Diseases, https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciac899/6835900, https://c19p.org/levin4

11. Hites et al., Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): a phase 3, randomized, double-blind, placebo-controlled trial

226 patient tixagevimab/cilgavimab late treatment RCT: 40% lower mortality (p=0.17), 18% worse 7-point scale results (p=0.52), 1% faster recovery (p=0.93), and 9% higher hospital discharge (p=0.49).
RCT 173 hospitalized COVID-19 patients showing no significant difference in clinical status, time to recovery, viral clearance, or mortality with tixagevimab/cilgavimab. Mortality was lower, without statistical significance. The trial was terminated early due to concerns about reduced efficacy against circulating variants.
Feb 2024, J. Infection, https://www.sciencedirect.com/science/article/pii/S0163445324000549, https://c19p.org/hites

12. Solera et al., Longitudinal outcomes of COVID-19 in solid organ transplant recipients from 2020 to 2023

1,975 patient tixagevimab/cilgavimab prophylaxis study: 26% lower severe cases (p=0.48).
Retrospective 1,975 solid organ transplant recipients with COVID-19 showing lower risk of severe cases with tixagevimab/cilgavimab prophylaxis, without statistical significance.
Mar 2024, American J. Transplantation, https://www.sciencedirect.com/science/article/pii/S1600613524002077, https://c19p.org/solera2

13. Desai et al., Tixagevimab and Cilgavimab (Evusheld) as Pre-exposure Prophylaxis for COVID-19 in Patients With Inflammatory Bowel Disease: A Propensity Matched Cohort Study

782 patient tixagevimab/cilgavimab prophylaxis study: 12% lower hospitalization (p=0.81) and 35% more cases (p=0.18).
TriNetX PSM retrospective 408 IBD patients receiving tixagevimab/cilgavimab and matched controls, showing no significant difference in COVID-19 cases or hospitalization.
Sep 2023, Crohn's & Colitis 360, https://academic.oup.com/crohnscolitis360/article/5/3/otad047/7261634, https://c19p.org/desai3

14. Din et al., COVID-19 infection among CAR-T cell therapy recipients: A single center experience

64 patient tixagevimab/cilgavimab prophylaxis study: 19% lower hospitalization (p=0.77).
Retrospective 64 COVID+ CAR-T cell therapy recipients, showing lower hospitalization with tixagevimab/cilgavimab prophylaxis in unadjusted results, without statistical significance.
Aug 2023, Hemasphere, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429980/, https://c19p.org/din

15. Lombardi et al., Preliminary Evidence of Good Safety Profile and Outcomes of Early Treatment With Tixagevimab/Cilgavimab Compared to Previously Employed Monoclonal Antibodies for COVID-19 in Immunocompromised Patients

108 patient tixagevimab/cilgavimab early treatment study: 368% higher mortality (p=0.32), 33% lower hospitalization (p=1), and 24% worse viral clearance (p=0.3).
Retrospective immunocompromised patients, showing no significant difference between tixagevimab/cilgavimab and other mAbs.
Jan 2023, MDPI AG, https://www.preprints.org/manuscript/202301.0359/v1, https://c19p.org/lombardi

16. Bes-Berlandier et al., Management of immunosuppression in lung transplant recipients and COVID-19 outcomes: an observational retrospective cohort-study

91 patient tixagevimab/cilgavimab prophylaxis study: 10% higher progression (p=1).
Retrospective 91 lung transplant recipients with COVID-19 showing no significant difference in poor outcomes with casirivimab/imdevimab or tixagevimab/cilgavimab prophylaxis in univariate analysis.
May 2024, BMC Infectious Diseases, https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-024-09269-1, https://c19p.org/besberlandiertc

17. Sindu et al., Pre-exposure Prophylaxis with Tixagevimab-cilgavimab did not Reduce Severity of COVID-19 in Lung Transplant Recipients with Breakthrough Infection

546 patient tixagevimab/cilgavimab prophylaxis PSM study: 96% higher ventilation (p=0.58), 210% higher ICU admission (p=0.33), 53% lower hospitalization (p=0.18), and 29% fewer symptomatic cases (p=0.14).
Retrospective 546 lung transplant recipients, 203 receiving tixagevimab/cilgavimab, and 343 out of state or declining treatment, showing a trend towards lower incidence of cases, but no significant difference in clinical outcomes.
May 2023, Transplantation Direct, https://journals.lww.com/10.1097/TXD.0000000000001485, https://c19p.org/sindu

Submit Corrections or Updates

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0